Breakthrough in CRISPR Gene Editing Accuracy
Our team has developed a new CRISPR variant with 99.9% on-target accuracy, significantly reducing off-target effects and opening new doors for therapeutic gene editing applications.
Stay informed about our latest breakthroughs, partnerships, and institutional developments.
Our team has developed a new CRISPR variant with 99.9% on-target accuracy, significantly reducing off-target effects and opening new doors for therapeutic gene editing applications.
KBR joins forces with MIT to accelerate AI-driven drug discovery for rare diseases, combining computational expertise with experimental validation.
State-of-the-art facility expands our capabilities in structural biology and protein characterization with next-generation mass spectrometry instruments.
National Institutes of Health awards five-year grant to support KBR-led consortium investigating novel therapeutic approaches for rare genetic disorders.
The 8th Annual KBR Research Symposium will be held September 12-13, 2026 in Kingston, NY. Keynote speakers from Stanford, MIT, and EMBL confirmed.